Close Menu

NEW YORK – JP Morgan said Wednesday that it has downgraded GenMark Diagnostics' stock to Neutral from Overweight and lowered the molecular diagnostic firm's December 2020 stock price target to $7 from $11.

The investment bank said Carlsbad, California-based GenMark experienced healthy momentum this year in placements of its ePlex molecular diagnostic analyzers, but reimbursement and competitive pressures pose a risk to its business outlook.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.